Karol Watson

Our very own @kewatson co-authored @CircAHA editorial calling 2026 dyslipidemia guidelines "a more precise individualized & equitable" framework for ASCVD prevention. ABC members co-wrote the guidelines. Now they're leading the conversation. buff.ly/CaKrb9D

#ACC26 finishes & as always proud of our @UCLAHealth presence, led by our housestaff & alumni! 🔥work with 25+ abstracts/talks/more 🙏 to the mentors who inspire them And congrats to @ACCinTouch 🌟#KatieBerlacher whose MedEd impact reaches farther than u will ever know ❤️

@kewatson @docHJ @utmbcardiology x.com/bogdienache/st…

@docHJ @utmbcardiology Absolutely NOT safer stroke prevention.

@dranulala @IcahnMountSinai @MountSinaiHeart @robmentz @DrMarthaGulati @ShashankSinhaMD @JasonKatzMD @BiykemB @AnkurKalraMD @purviparwani @AndrewJSauer @RyanTedfordMD @noshreza So well deserved 👏🏽👏🏽👏🏽

Grateful to share that I’ve been promoted to Professor of Medicine @IcahnMountSinai @MountSinaiHeart Titles are milestones — and their real meaning lies in people, purpose, and continued growth. For me, this “milestone” reflects the sacred privilege of caring for patients, mentoring (really learning from) trainees, collaborating with brilliant colleagues, and contributing to how we understand, prevent, and treat heart failure through a lens that honors the whole person: in body, mind & spirit. I remain deeply grateful for every mentor, sponsor, partner, and learner who has shaped/is shaping/will shape my path — and for the trust of the patients and families who remind us of the profound interconnectedness of health, humanity, and the heart. 🫀 Looking forward to continuing this work with reverence & curiosity, rooted in community. Deeply grateful. 🙏🏽 @DLBHATTMD

It’s a #MATCH 💙🎊💛! Welcome to the newest members of our #Bruinhearts Family! We are so thrilled to have you all join us, and congratulations on your incredible achievements! The future of cardiology is bright and forever beats blue and gold ⭐️💫.

A BIG enthusiastic welcome to our new #bruinhearts @uclaCVfellows class!! We are so excited to have you join the family and be the field's next superstars!! @kewatson @netta_doc @HayaseJustin @arafiqmd1 @DOM_UCLA @IntMedAbel

@rblument1 presenting at #AHA25 on the intensity & timing of LDL lowering 🫀elevated LDL exposure time matters 🫀risk scores don’t go young enough- waiting to 40 to treat may be too late 🫀don’t wait: cross the line early @CiccaroneCenter @MichaelJBlaha @SethShayMartin @drstaceyrosen

CORE TIMi 72a/b presented as #LBCT #AHA25 studying olezarsen in severe hypertriglyceridemia with primary endpoint percent change in TG ♥️ Global study 1063 patients ♥️placebo compared with two doses ♥️1/4 female 👎🏽 🎯62% placebo control ⤵️ in TG 🎯 significant ⤵️ in non HDL: many achieved TG <150 & 85% <500! 👏🏽 🎯⤵️ in pancreatitis with tx NNT=4 🎯 safe esp at 50 mg dose 📎 nejm.org/doi/full/10.10… @ionispharma @NEJM

@DrMarthaGulati @iamritu @purviparwani @AHAScience @kewatson @JoChikweMD @dramitkhera 2 studies with impressive results of major reduction in Triglycerides and its effects in pts with high TG

Congrats & so thrilled for @UCLAHealthJCCC @UCLAHealth @DOM_UCLA #bruinhearts @ucla_wic @A_SteinMerlob winning the #YIA at #GCOS2025! 🙏 to @alan_garfinkel, @uclaCVfellows @kewatson @IntMedAbel #STAR leadership for your amazing mentorship for this #cardioonc🌟! @ICOSociety

Look Carefully for Causes of Myocardial Infarction in Younger Patients: jwat.ch/4oGfrwf @kewatson #CardioTwitter

Remarkable contributions to the field expanding a life saving therapy-great to see the two legends on the stage for 20th Annual VT Symposium- Mark Josephson Memorial Lecture. Our beloved Mark would indeed be smiling! @DrRoderickTung @VTSymposium

So lovely to spend time with some of our favorite people! Lovely to be able to have a hike & breakfast with @rblument1 & @WendyPost9 today before their wedding they are attending tonight & before @SmidtHeart GR on Tuesday! We loved being able to see you both! #CVPrev & #friendship are some of the best things in life!

Amgen announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that evolocumab significantly reduced the risk of MACE in individuals without a prior history of heart attack or stroke 12,000 high-risk patients, median of 4.5 years @kewatson

Data from the COMBINE-AF substudy suggest it may be safe and beneficial to switch frail older patients with atrial fibrillation from warfarin to a direct-acting oral anticoagulant. jwat.ch/4nQWyGo #CardioTwitter @kewatson

Statins have been contraindicated during pregnancy because of teratogenic effects in animal studies. Now, using Norwegian registry data, researchers have evaluated statin exposure and congenital malformations in more than 800,000 pregnancies. jwat.ch/3K9fCRE @kewatson

A privilege to listen to GDMT masterclass with Dr Gregg Fonarow @gcfmd at @UCLA_HF Symposium Evidence, nuance, and practical takeaways for #HFmrEF #HFpEF care

@alxbenevides @ehj_ed @ESC_Journals @DrMarthaGulati @MihaiTrofenciuc @ShelleyZieroth @AnastasiaSMihai @purviparwani @SamRRazaMD @biljana_parapid @AlainBouchardmd @AliElzieny @kewatson convinced me, if a physiologic normal LDL-C is 20-40 mg/dL and Huygens and PACMAN-AMI demonstrate clear regression of plaque <40 mg/dL… then <<<40 mg/dL should be the optimal target. Stabilization and regression of plaque is the goal! @FamilyHeartFdn #FHFSummit25

A New Expert Consensus Document on Pericardial Diseases Dr. @kewatson summarizes key recommendations of an American College of Cardiology statement on diagnosis and management of pericarditis. jwat.ch/4mXVtwt #CardioTwitter #guidelines